)
George Dorfman
Associate Director, Business Development, Cell and Gene Therapy,
Mission Bio
George has 13 years experience in the translational oncology and diagnostics spaces, working with industry clients across all -omics modalities. His current role at Mission Bio enables partners to develop GxP assays incorporating numerous CQAs in the cell and gene therapy sectors, and liaising deployment of these assays to clients and their CDMOs. Prior to Mission Bio, George headed up strategic pharmaceutical alliances at Metabolon, and technical applications in clinical Dx development and deployment at Mitra Biotech. George’s research at Rutgers University and the Cleveland Clinic focused on biomaterial engineering for iPS and iN grafting and preferred lineage differentiation applications.
Sessions
-
25-Jun-2024Salon BSponsor Poster Presentation: Quantification of Single Cell Vector Copy Number in CAR T Cell Products Utilizing a Novel Microfluidic Technology
-
18-Jun-2024Salon APoster Session: Quantification of Single Cell Vector Copy Number in CAR T Cell Products Utilizing a Novel Microfluidic Technology